THE BEST SIDE OF OXYGEN CHAMBER MACHINE

See Whole Prescribing Information OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed just after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or soon after 3 or more traces of systemic therapy that features autologous HSCT.